

## **CARDIOVASCULAR DRUGS IN THE TREATMENT SOCIALLY SIGNIFICANT DISEASES IN KAZAKHSTAN**

<sup>1</sup> Datkhaev U.M., <sup>1</sup> Shopabaeva A.R., <sup>2</sup> Khimenko S.V., <sup>1</sup> Mussabek G.K.

<sup>1</sup> S.D. Asfendiyarov Kazakh National Medical University, Almaty, Kazakhstan

<sup>2</sup> National University of Pharmacy, Kharkiv, Ukraine.

mussabek-gulnar@mail.ru

Within the framework of the State Programme for Development of public health of the Republic of Kazakhstan “Salamatty Kazakhstan” for 2011 - 2015 years, an improvement of diagnostic methods, treatment and rehabilitation of basic social diseases, first of all cardiovascular ones are scheduled. According to the World Health Ranking (2012), coronary (ischemic) heart disease was the cause of 48,332 deaths, or took 31.27% among 50 leading causes of the death in Kazakhstan in 2011, and together with data on mortality from coronary heart disease, stroke and hypertension, pointed percentage rises up to 50.11%.

The aim of our study was to investigate the pharmaceutical market in the Republic of Kazakhstan in the group of drugs used in the treatment of cardiovascular diseases, that has a leading position in the structure of morbidity in the country.

The study was conducted using data on the volume of retail sales and procurement of finished medicines in the pharmaceutical market of Kazakhstan for the year 2012, received from «Vi-ORTiS» consulting agency.

We determined the proportion of cardiovascular drugs, which was 8.9% in the amount of \$ 140.8 million. The total range of the studied group of drugs includes 809 specimens for the treatment of cardiovascular disease (with C code within ATC classification). The main supplier countries of these drugs: Germany (105 specimens), India (80) Russia (79) Ukraine (74), Hungary (54). Producers from 35 different countries deliver 340 kinds of cardiovascular drugs on the pharmaceutical market of Kazakhstan. Domestic manufacturers (12 companies) deliver only 77 kinds of medicines. It is found that 101 ATC-C codes of the 128 ones do not contain cardiovascular drugs of Kazakh producers.

Thus, we have determined the perspective directions for development of domestic production in the field of cardiovascular drugs.